Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
13.95 (1y: +23%)
Market Cap 413.3 M P/E(ttm) 68.20
Enterprise Value 456.21 M P/B 1.60
BABY- NAS (USA)
Natus Medical, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$13.95
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 0.702
BABY's Cash to Debt is ranked higher than
55% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. BABY: 0.702 )
BABY' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 0.7
Equity to Asset 0.686
BABY's Equity to Asset is ranked higher than
70% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. BABY: 0.686 )
BABY' s 10-Year Equity to Asset Range
Min: -1.71   Max: 0.94
Current: 0.69
-1.71
0.94
Interest Coverage 12.1
BABY's Interest Coverage is ranked higher than
65% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. BABY: 12.1 )
BABY' s 10-Year Interest Coverage Range
Min: 12   Max: No Debt
Current: 12.1
F-Score: 6
Z-Score: 2.98
M-Score: -2.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) 1.80
BABY's Operating margin (%) is ranked higher than
59% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. BABY: 1.80 )
BABY' s 10-Year Operating margin (%) Range
Min: -32.5   Max: 15.7
Current: 1.8
-32.5
15.7
Net-margin (%) 1.3
BABY's Net-margin (%) is ranked higher than
61% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. BABY: 1.3 )
BABY' s 10-Year Net-margin (%) Range
Min: -27.6   Max: 14.3
Current: 1.3
-27.6
14.3
ROE (%) 1.4
BABY's ROE (%) is ranked higher than
61% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. BABY: 1.4 )
BABY' s 10-Year ROE (%) Range
Min: -13.6   Max: 8.9
Current: 1.4
-13.6
8.9
ROA (%) 1
BABY's ROA (%) is ranked higher than
62% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. BABY: 1 )
BABY' s 10-Year ROA (%) Range
Min: -12.6   Max: 7.9
Current: 1
-12.6
7.9
ROC (Joel Greenblatt) (%) 5.60
BABY's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. BABY: 5.60 )
BABY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -107   Max: 73.4
Current: 5.6
-107
73.4
Revenue Growth (%) 13.8
BABY's Revenue Growth (%) is ranked higher than
95% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. BABY: 13.8 )
BABY' s 10-Year Revenue Growth (%) Range
Min: -51.4   Max: 27.6
Current: 13.8
-51.4
27.6
EBITDA Growth (%) -6.9
BABY's EBITDA Growth (%) is ranked lower than
61% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. BABY: -6.9 )
BABY' s 10-Year EBITDA Growth (%) Range
Min: -6.9   Max: 134.7
Current: -6.9
-6.9
134.7
EPS Growth (%) -24
BABY's EPS Growth (%) is ranked lower than
65% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. BABY: -24 )
BABY' s 10-Year EPS Growth (%) Range
Min: -43.1   Max: 18.9
Current: -24
-43.1
18.9
» BABY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

BABY Guru Trades in Q2 2012

Diamond Hill Capital 28,100 sh (+74.53%)
Jim Simons 65,474 sh (-12.09%)
» More
Q3 2012

BABY Guru Trades in Q3 2012

Diamond Hill Capital 29,300 sh (+4.27%)
Jim Simons 19,874 sh (-69.65%)
» More
Q4 2012

BABY Guru Trades in Q4 2012

Paul Tudor Jones 23,700 sh (New)
Steven Cohen 9,905 sh (New)
Jim Simons 45,475 sh (+128.82%)
Diamond Hill Capital 42,315 sh (+44.42%)
» More
Q1 2013

BABY Guru Trades in Q1 2013

Steven Cohen 13,852 sh (+39.85%)
Diamond Hill Capital 54,335 sh (+28.41%)
Jim Simons Sold Out
Paul Tudor Jones 17,100 sh (-27.85%)
» More
» Details

Insider Trades

Latest Guru Trades with BABY



No Insider Trades Found!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 69.00
BABY's P/E(ttm) is ranked lower than
61% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 22.90 vs. BABY: 69.00 )
BABY' s 10-Year P/E(ttm) Range
Min: 11.26   Max: 699.33
Current: 69
11.26
699.33
P/B 1.60
BABY's P/B is ranked higher than
76% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. BABY: 1.60 )
BABY' s 10-Year P/B Range
Min: 0.78   Max: 5.9
Current: 1.6
0.78
5.9
P/S 1.30
BABY's P/S is ranked higher than
73% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. BABY: 1.30 )
BABY' s 10-Year P/S Range
Min: 0.16   Max: 8.5
Current: 1.3
0.16
8.5
PFCF 83.10
BABY's PFCF is ranked lower than
60% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 21.03 vs. BABY: 83.10 )
BABY' s 10-Year PFCF Range
Min: 12.8   Max: 556
Current: 83.1
12.8
556
EV-to-EBIT 47.6
BABY's EV-to-EBIT is ranked lower than
60% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 18.50 vs. BABY: 47.6 )
BABY' s 10-Year EV-to-EBIT Range
Min: 5.7   Max: 409.7
Current: 47.6
5.7
409.7
Shiller P/E 47.7
BABY's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Devices industry.

( Industry Median: vs. BABY: 47.7 )
BABY' s 10-Year Shiller P/E Range
Min: 19.55   Max: 2156
Current: 47.7
19.55
2156

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 5.1
BABY's Price/Net Current Asset Value is ranked higher than
83% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. BABY: 5.1 )
BABY' s 10-Year Price/Net Current Asset Value Range
Min: 3.9   Max: 28.8
Current: 5.1
3.9
28.8
Price/Tangible Book 5.4
BABY's Price/Tangible Book is ranked lower than
51% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. BABY: 5.4 )
BABY' s 10-Year Price/Tangible Book Range
Min: 0.8   Max: 66.7
Current: 5.4
0.8
66.7
Price/DCF (Projected) 1.2
BABY's Price/DCF (Projected) is ranked higher than
78% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. BABY: 1.2 )
BABY' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 5.1
Current: 1.2
0.8
5.1
Price/Median PS Value 0.6
BABY's Price/Median PS Value is ranked higher than
90% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. BABY: 0.6 )
BABY' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 3
Current: 0.6
0.2
3
Price/Graham Number 5.2
BABY's Price/Graham Number is ranked lower than
63% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. BABY: 5.2 )
BABY' s 10-Year Price/Graham Number Range
Min: 1.7   Max: 11.6
Current: 5.2
1.7
11.6
Earnings Yield (Greenblatt) 2.10
BABY's Earnings Yield (Greenblatt) is ranked higher than
64% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. BABY: 2.10 )
BABY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 17.5
Current: 2.1
0.2
17.5
Forward Rate of Return (Yacktman) 3.14
BABY's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. BABY: 3.14 )
BABY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.4   Max: 86.5
Current: 3.14
-4.4
86.5

Business Description

Natus Medical Incorporated was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. The Company is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company's product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The company products category includes: Hearing; Monitoring Systems for Neurology; and Newborn Care. Hearing includes products for newborn hearing screening and diagnostic hearing assessment. Its diagnostic hearing assessment products consist of the Navigator Pro system, the Scout Sport portable diagnostic device, the HINT PRO, the AuDX PRO, the Cochlea-Scan, and the Centor. Monitoring Systems for Neurology includes products for diagnostic electroencephalography, diagnostic sleep analysis, electromyography, intra-operative monitoring, newborn brain monitoring, and assessment of balance and mobility disorders. Newborn Care includes products for the treatment of brain injury and jaundice in newborns. It purchases materials and components from qualified suppliers that are subject to its quality specifications and inspections. It conducts quality audits of its key suppliers, several of which are experienced in the supply of components to manufacturers of finished medical devices, or supplies for use with medical devices. Most of its purchased components are available from more than one supplier. The Company faces competition from other companies in all of its product lines. The Company's competitors range from small privately-held companies to multinational corporations and their product offerings vary in scope and breadth. The Company is subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
» More Articles for BABY

Headlines

Articles On GuruFocus.com
Natus Medical Inc. Reports Operating Results (10-Q) Nov 05 2010 
David Nierenberg’s Top Holdings: MOVE, ESIO, BABY, RSYS, HPY, SPN Aug 27 2010 
Natus Medical Inc. (BABY) VP Finance and CFO Steven J Murphy sells 1,814 Shares Aug 19 2010 
Natus Medical Inc. (BABY) President and CEO James B Hawkins sells 6,796 Shares Aug 19 2010 
Natus Medical Inc. Reports Operating Results (10-Q) Aug 06 2010 
Natus Medical Inc. (BABY) VP Finance and CFO Steven J Murphy sells 1,395 Shares Aug 05 2010 
Natus Medical Inc. (BABY) President and CEO James B Hawkins sells 4,081 Shares Aug 05 2010 
Natus Medical Inc. Reports Operating Results (10-Q) May 07 2010 
Natus Medical Inc. Reports Operating Results (10-Q) Nov 09 2009 
Natus Medical to Acquire Alpine Biomed Sep 14 2009 

More From Our Partners
MDT Expands Spine-Line in Europe - Analyst Blog Jun 19 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK